Prof Kantarjian speaks to ecancer about a study presented at ASH 2020 regarding a phase 2 trial; long-term follow-up of the combination of low-intensity chemotherapy plus inotuzumab ozogamicin with or without blinatumomab in patients with relapsed-refractory Philadelphia chromosome-negative acute lymphoblastic leukaemia.
He says that the outcome of patients with relapsed-refractory (R/R) acute lymphoblastic leukaemia (ALL) is poor.
Inotuzumab ozogamicin and blinatumomab are highly active single agents in R/R ALL. The combination of inotuzumab with low-intensity mini-hyper-CVD chemotherapy showed encouraging results in this patient population.
The sequential addition of blinatumomab optimises the efficacy of the regimen, reduce its toxicities, and further improve outcomes in R/R ALL.
He says that the aim of the analysis was to evaluate the efficacy and safety of inotuzumab ozogamicin plus low-intensity chemotherapy with or without blinatumomab in R/R ALL.
Prof Kantarjian then explains the key results from this study and how they can impact the future treatment of Ph- ALL.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.